Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
Date: June 13, 2013
Company: Jazz Pharmaceuticals Plc (Ireland)
Event: Amendment of Credit Facility and Term Loan Refinancing (Item 2.03)
The Company entered into Amendment No. 1 to its Credit Agreement with Barclays Bank PLC as administrative agent. This amendment refinances existing term loans and expands the revolving credit facility.
Key Financial Metrics and Debt Structure
| Facility Component | Amount | Details |
|---|---|---|
| Tranche 1 Term Loans | $557,187,500 | Refinanced $457,187,500 of original term loans; $100,000,000 excess proceeds available for general corporate purposes. |
| Revolving Credit Facility | $200,000,000 | Increased from $100,000,000 under the original agreement. No amounts borrowed to date. |
| Term Loan Maturity | June 12, 2018 | Same as original term loans. |
| Revolving Maturity | June 12, 2017 | Same as original revolving facility. |
| Term Loan Interest Rate | LIBOR + 2.75% or Prime + 1.75% | Subject to LIBOR floor of 0.75% and Prime floor of 1.75%. |
| Revolving Interest Rate | LIBOR + 2.50% or Prime + 1.50% | Subject to reduction based on secured leverage ratio. |
Amortization: Tranche 1 Term Loans amortize at 1% of the original principal amount annually in equal quarterly installments.
Collateral: Secured by a perfected security interest in all tangible and intangible assets of the Loan Parties and 65% of voting equity interests of certain subsidiaries.
Material Changes Versus Prior Period
- Debt Increase: Total term loan principal increased by $100,000,000 (from $457,187,500 to $557,187,500).
- Liquidity Expansion: Revolving credit facility capacity doubled from $100,000,000 to $200,000,000.
- Refinancing: Full repayment of original term loans using proceeds from the new Tranche 1 Term Loans.
Guidance, Covenants, and Risks
Use of Proceeds: The $100,000,000 excess from the term loan and future revolving loans are intended for general corporate purposes, including business development activities.
Financial Covenants: The agreement requires the maintenance of a maximum secured leverage ratio. Mandatory prepayments of 50% of excess cash flow are required beginning in fiscal year 2014, subject to reduction based on leverage ratios.
Risks and Contingencies:
- Events of Default: Include failure to make payments, covenant breaches, insolvency, change in control, and material misrepresentations.
- Consequences: Upon default, lenders may terminate commitments and declare all obligations immediately due and payable.
- Forward-Looking Statements: The Company notes risks regarding the adequacy of cash resources, ability to meet debt service obligations, and execution of business development opportunities.
Investor Verification Checklist
- Verify the full text of Amendment No. 1 (Exhibit 10.1) for specific covenant thresholds and definitions of "excess cash flow."
- Confirm the Company's current secured leverage ratio to assess compliance with the maximum leverage covenant.
- Review the Company's most recent Form 10-Q (ended March 31, 2013) for detailed risk factors and cash flow projections.
- Monitor the utilization of the $200,000,000 revolving facility, as no amounts have been drawn to date.
- Assess the impact of mandatory prepayments starting in fiscal year 2014 on future liquidity.